Table 2

Number of persons, crude incidence, average follow-up time and HRs for the different cervical outcomes under study

Outcome definitionCohortNumber of patients at riskMean follow-upNumber of eventsCrude incidence per 100 000 person-yearsHR*HR*
First screening with normal resultTNFi90723.29436214 5991.01 (0.98 to 1.05)
Biologics-naive RA33 2533.5710 9589224Ref1.08 (1.06 to 1.10)
General population287 6024.18114 9439556Ref
CIN 1TNFi89436.105295.31.23 (0.87 to 1.74)
Biologics-naive RA32 9475.269957.1Ref1.53 (1.23 to 1.89)
General population285 2326.6685244.8Ref
CIN 2+TNFi90186.1175136.01.36 (1.01 to 1.82)
Biologics-naive RA33 1305.2713778.5Ref1.39 (1.16 to 1.66)
General population286 7316.67133269.7Ref
Invasive cervical cancer, overallTNFi96296.151423.72.10 (1.04 to 4.23)
Biologics-naive RA34 9845.272513.6Ref1.09 (0.71 to 1.65)
General population300 3316.6827513.7Ref
Invasive cervical cancer†TNFi1076.761138.2
Biologics-naive RA2605.472140.6Ref
General population21196.72535.1Ref
Invasive cervical cancer§TNFi6856.05372.3
Biologics-naive RA20365.06438.8Ref
General population15 0696.472020.5Ref
Invasive cervical cancer¶TNFi64186.501024.03.77 (1.35 to 10.48)
Biologics-naive RA18 5205.4776.9Ref0.78 (0.36 to 1.70)
General population162 5437.081129.7Ref
  • *Stratified on decade of birth and adjusted for educational level, number of cervical screens past five years, comorbidities, marital status and total days spent in hospital during last five years, also implicitly adjusted for age since age was used as the model's timescale.

  • †In individuals with a history of CIN 1 or CIN 2+ during the five years before start of follow-up.

  • ‡Not computed due to low number of events.

  • §in individuals with a history of CIN 1 or CIN 2+ ever.

  • ¶In individuals with a normal screening test as the most recent screening test less than five years before start of follow-up.

  • CIN, cervical intraepithelial neoplasia; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.